Clinical Trial

Optimal Timing of Hepatitis B Vaccination After Transplants

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.
Trial Details
NCT Number NCT06888479
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
Enrollment 1,500 participants
Start Date 2025-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-21